Spago Nanomedical AB Logo

Spago Nanomedical AB

Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.

SPAGO | ST

Overview

Corporate Details

ISIN(s):
SE0004899474 (+2 more)
LEI:
549300DNLTVJ4OGO5X40
Country:
Sweden
Address:
Scheelevägen 22, 223 63 Lund
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Spago Nanomedical AB is a clinical-stage nanomedicine company developing products for the precise diagnosis and treatment of cancer and other severe diseases. The company's development is based on a proprietary platform of polymeric materials. Its portfolio includes two primary projects: Tumorad®, a targeted radionuclide therapy program, and SpagoPix, a novel MRI contrast agent. The Tumorad® candidate, 177Lu-SN201, is in Phase I/IIa clinical trials for treating advanced cancers by accumulating in tumors. The SpagoPix candidate, pegfosimer manganese, is designed to provide selective contrast enhancement in tumors and other tissues, with clinical data showing efficacy in breast cancer and endometriosis lesions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Spago Nanomedical AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Spago Nanomedical AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Spago Nanomedical AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Develops DNA vaccines and therapeutics for companion animals and livestock.
South Korea 222670
Pluri Inc. Logo
Develops placenta-based cell therapeutics using a proprietary 3D cell-expansion platform.
Israel PLUR
A global supplier of generic APIs using AI to accelerate drug development.
South Korea 041910
Poltreg S.A. Logo
Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.
Poland PTG
PolyPeptide Group AG Logo
A global CDMO specializing in peptide and oligonucleotide APIs for pharma and biotech partners.
Switzerland PPGN
Develops sensitive point-of-care biomarker diagnostics for human and animal health.
South Korea 335810
A global CDEMO offering end-to-end solutions for antibody therapeutics and biologics.
South Korea 334970
Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.
Singapore 950210
Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.
South Korea 296160
PROTEINA CO.,LTD. Logo
A biotech firm specializing in proteomics for drug discovery and diagnostics in oncology.
South Korea 468530

Talk to a Data Expert

Have a question? We'll get back to you promptly.